Moleculin Biotech (MBRX) Total Current Liabilities (2015 - 2026)
Moleculin Biotech (MBRX) posted quarterly Total Current Liabilities of $6.9 million for Q4 2025, up 27.9% year-over-year from $5.4 million in Q4 2024, and up 20.63% quarter-over-quarter from $5.7 million in Q3 2025.
Moleculin Biotech (MBRX) Total Current Liabilities (2015 - 2026) Analysis & Trends
Moleculin Biotech's Total Current Liabilities history runs 11 years deep, the most recent figure standing at $6.9 million for Q4 2025.
- In Q4 2025, Total Current Liabilities rose 27.9% year-over-year to $6.9 million; the TTM figure through Dec 2025 stood at $6.9 million (up 27.9% YoY), while the FY2025 annual figure was $6.9 million, up 27.9% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $6.9 million, up from $5.7 million in the prior quarter.
- The five-year high for Total Current Liabilities was $7.9 million in Q2 2025, with the low at $3.4 million in Q2 2021.
- The 5-year median for Total Current Liabilities is $5.5 million (2024), against an average of $5.4 million.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 74.9% in 2022, then plunged 38.89% in 2023.
- Moleculin Biotech's Total Current Liabilities stood at $3.6 million in 2021, then soared by 33.05% to $4.8 million in 2022, then soared by 41.42% to $6.8 million in 2023, then fell by 21.36% to $5.4 million in 2024, then rose by 27.9% to $6.9 million in 2025.
- Business Quant data shows MBRX's Total Current Liabilities at $6.9 million in Q4 2025, $5.7 million in Q3 2025, and $7.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Moleculin Biotech | 3.35 Mn | 3.35 Mn | - | 9.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.31 Mn |
| Dec 31, 2025 | 6.85 Mn |
| Sep 30, 2025 | 5.68 Mn |
| Jun 30, 2025 | 7.91 Mn |
| Mar 31, 2025 | 6.90 Mn |
| Dec 31, 2024 | 5.36 Mn |
| Sep 30, 2024 | 5.59 Mn |
| Jun 30, 2024 | 5.75 Mn |
| Mar 31, 2024 | 5.41 Mn |
| Dec 31, 2023 | 6.82 Mn |
| Sep 30, 2023 | 3.89 Mn |
| Jun 30, 2023 | 6.55 Mn |
| Mar 31, 2023 | 5.03 Mn |
| Dec 31, 2022 | 4.82 Mn |
| Sep 30, 2022 | 6.36 Mn |
| Jun 30, 2022 | 5.86 Mn |
| Mar 31, 2022 | 4.83 Mn |
| Dec 31, 2021 | 3.62 Mn |
| Sep 30, 2021 | 3.66 Mn |
| Jun 30, 2021 | 3.35 Mn |